Global Kirsten Rat Sarcoma (KRAS) Market Segmentation, By Cancer Type (Breast Cancer, Pancreatic Cancer, Colon Cancer, Lung Cancer, Others), Application (Development and Drug Formulation, Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, Personalised Medicine, Predictive, Prognostics, Research and Development, Risk Assessment, Therapeutic) End User (Academic and Cancer Research Institutes, Ambulatory Surgical Centers, Cancer Diagonostic Centers and Reasearch Laboratories, Clinic Laboratories, Contract Research Organizations(CRO), Healthcare IT/Big Data Companies, Hospitals, Pharma and Biotech Companies) – Industry Trends and Forecast to 2032
Kirsten Rat Sarcoma (KRAS) Market Analysis
Newly reprogrammed metabolic pathways and oncometabolites influence the tumorigenic environment. The development of ways to modulate metabolic reprogramming in pancreatic cancer cells could pave the way for a novel treatment strategy. The primary metabolic pathways that provide acetyl-CoA and NADPH, which are required for lipid synthesis and cell proliferation in pancreatic cancer cells.
Kirsten Rat Sarcoma (KRAS) Market Size
Global Kirsten Rat Sarcoma (KRAS) market size was valued at USD 3.69 billion in 2024 and is projected to reach USD 3.37 billion by 2032, with a CAGR of 1.5% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
|
Attributes
|
Kirsten Rat Sarcoma (KRAS) Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Agilent Technologies Inc. (U.S), Illumina Inc. (U.S), Thermo Fisher Scientific Inc. (U.S), Abbott (U.S), NimaGen BV (Netherlands), Agena Bioscience Inc. (China), BML Inc. (Japan), Takara Bio Inc. (Japan), New England Biolabs (U.S), Amoy Diagnostics Co Ltd (Japan), Panagene (South Korea), EntroGen (U.S), Sysmex Corporation (Japan), Biocartis (Belgium)
|
|
Market Opportunities
|
|
Kirsten Rat Sarcoma (KRAS) Market Definition
Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven pancreatic cancer is extremely fatal, with a five-year survival rate of only 9%. Because of the specificities of pancreatic tumors, several treatment techniques such as chemotherapy, radiation, and immunotherapy showed very moderate efficacy. Surgery is the primary curative option in the early stages of the disease, however only in 20% of individuals with early stage disease.
Kirsten Rat Sarcoma (KRAS) Market Dynamics
Drivers
- Innovative development in the pharmaceuticals
The kirsten rat sarcoma (KRAS) market is widely supported by the accelerating trend of in vitro diagnostics and ongoing research in its treatment section. The need for Kirsten rat sarcoma has grown as the number of people diagnosed with lung cancer has increased (KRAS). The kirsten rat sarcoma (KRAS) market is expanding because of innovative pharmaceutical development and the production of new medications to battle various tumors. These factors are projected to fuel market expansion in the forecasted time range of 2025 to 2032.
- Rising demand for targeted therapies
According to the results of the analysis, the global KRAS inhibitor market is expected to exceed USD 4.5 billion by 2028, owing to rising demand for targeted medicines and increasing acceptance in cancer management. The research provides in-depth analysis of the pipeline therapeutics landscape and growth prospects for KRAS Inhibitor development. The paper covers the pipeline environment for this mechanism of action in depth and commercial information on already marketed KRAS inhibitors.
- Novel drugs and inhibitors
Lumakras has exhibited high acceptance rates in the market since its introduction, with global sales of around USD 90 million in 2021. The positive response to the innovative medicine has prompted more research and development efforts in this area. Adagrasib, JQ443, GDC-6036, BI 1823911, JNJ-74699157, MK-1084, and others are among the many possible KRAS inhibitors in development. Adagrasib is one of the most advanced KRAS inhibitors currently in phase-III clinical trials, whereas the others are mostly in phase-I/II trials.
Opportunities
Biomarker testing, which informs therapy options during disease, is an unmet need with improvements in precision medicine. After receiving US regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with Lumakras, Qiagen 2021 announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RCQ PCR kit (therascreen KRAS Kit). The diagnostic test will be marketed in the United States in collaboration with Labcorp.
Restraints/Challenges
Some restrictions, such as a lack of understanding regarding the benefits of Kirsten rat sarcoma (KRAS) research, may limit market expansion. Clinical and laboratory diagnostics demand high-cost funding. Major studies are still in the works. These factors may hinder the market growth.
This kirsten rat sarcoma (KRAS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kirsten rat sarcoma (KRAS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Kirsten Rat Sarcoma (KRAS) Market Scope
The kirsten rat sarcoma (KRAS) market is segmented on the basis of type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Breast Cancer
- Pancreatic Cancer
- Colon Cancer
- Lung Cancer
- Others
Application
- Development and Drug Formulation
- Development of Molecular Diagnostics
- Disease Diagnostics
- Drug Discovery and Development
- Personalised Medicine
- Predictive
- Prognostics
- Research and Development
- Risk Assessment
- Therapeutic
End-User
- Academic and Cancer Research Institutes
- Ambulatory Surgical Centers
- Cancer Diagonostic Centers and Research Laboratories
- Clinic Laboratories
- Contract Research Organizations (CRO)
- Healthcare IT/Big Data Companies
- Hospitals
- Pharma and Biotech Companies
Kirsten Rat Sarcoma (KRAS) Market Regional Analysis
The kirsten rat sarcoma (KRAS) market is analyzed and market size insights and trends are provided by country, type, application and end-user as referenced above.
The countries covered in the kirsten rat sarcoma (KRAS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the kirsten rat sarcoma (KRAS) market because of the rising occurrence of cancer linked to the kirsten rat sarcoma (KRAS) mutation and increased R&D spending.
U.S. is dominating the North America kirsten rat sarcoma (KRAS) market for the reagents and kits segment because of the high prevalence of the kirsten rat sarcoma (KRAS) mutation and the penetration of penetration innovative products.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Kirsten Rat Sarcoma (KRAS) Market Share
The kirsten rat sarcoma (KRAS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to kirsten rat sarcoma (KRAS) market.
Kirsten Rat Sarcoma (KRAS) Market Leaders Operating in the Market Are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Qiagen (Germany)
- Agilent Technologies Inc. (U.S)
- Illumina Inc. (U.S)
- Thermo Fisher Scientific Inc. (U.S)
- Abbott (U.S)
- NimaGen BV (Netherlands)
- Agena Bioscience Inc. (China)
- BML Inc. (Japan)
- Takara Bio Inc. (Japan)
- New England Biolabs (U.S)
- Amoy Diagnostics Co Ltd (Japan)
- Panagene (South Korea)
- EntroGen (U.S)
- Sysmex Corporation (Japan)
- Biocartis (Belgium)
Latest Developments in Kirsten Rat Sarcoma (KRAS) Market
- In January 2021, For Advanced Comprehensive Genomic Profiling, Illumina, Inc. established partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck. The collaborations will help the organisation achieve its goal of developing standardised precision oncology tools. It would result in good market growth
- In October 2020, Thermo Fisher Scientific Inc. announced that it would extend its relationship with Symphogen in order to provide breakthrough cancer treatments by optimising protein characterization and quality monitoring mass spectrometry procedures. To improve drug delivery, the companies can provide compliance-ready mass spectrometer solutions to the biopharmaceutical industry. It would result in good market growth
SKU-